The FDA has sent out a Complete Response Letter to Transcept Pharma regarding its resubmitted New Drug Application (NDA) for...
The FDA has approved Intermezzo (zolpidem tartrate sublingual tablets), from Transcept Pharmaceuticals, for use as needed to treat insomnia characterized...
Transcept Pharma had resubmitted its drug application for its middle-of-the-night insomnia drug Intermezzo (zolpidem tartrate sublingual tablet) in January 2011....